Hybrigenics Re-brands to 'ATON' as Company Signals New Global Vision and Strategy to Advance Breakthrough Treatments
26 9월 2023 - 10:00PM
Business Wire
ATON commits €15million to support its new
growth and development strategy over next three years
Hybrigenics, a leading French publicly listed bioscience firm,
has today announced its re-brand to 'ATON' as it signifies the
culmination of a transformative shift in its vision and strategy
that began two years ago. Developed over the last year, the new
identity and re-branding plan aligns with ATON's wider commitment
to positioning the company as a prominent player in the
pharmaceutical and biotechnology industry; and will support
continued growth and profitability.
The rebrand also supports the company’s ongoing plans to
advancing breakthrough treatments and create, support, and energise
next-generation life sciences enterprises to help deliver today’s
and tomorrow’s medicines. To advance this, ATON has committed a
further €15million over the next three years; and follows the
recent completion of a two-year €10million investment strategy.
Founded in 1998, and headquartered in France, ATON is a leading
bioscience company listed on the Euronext Paris. It has four
companies within the ATON group:
- Bcell Design designs, produces and distributes best-in-class
antibodies for the in-vitro diagnostics (IVDs) industry, the
research and the development of therapeutics to increase patient
safety;
- Inoviem Scientific supports biopharmaceutical companies by
accelerating and securing the entire drug development process.
- PIMS Technology is patented technology and equipment designed
to personalise treatment, ensuring the right treatments are
provided to the right patient in a more cost-effective way
- Stemcis develops surgical kits for lipofilling procedures, and
provides high-quality, efficient and easy-to-use equipment for fat
transfer procedures.
The bioscience firm has a broad focus and covers all therapeutic
areas, including cancer, cardiology, dermatology, neurology,
haematology, and inflammatory conditions, such as Crohn’s disease,
and allergies. Through its products and services, the company
supports its partners and customers to make quick decisions and
take better care of patients.
ATON's decision to re-brand reflects its bold aspirations and
dedication to driving innovation in bioscience. The company's new
name represents its core principles of leading-edge technology and
solutions, as it looks to spearhead the next generation of
breakthrough treatments.
Central to ATON's vision is the doubling of its workforce over
the next two years, a strategic move to strengthen its capabilities
and accelerate research and development efforts. By expanding its
team of experts and leveraging their diverse talents, ATON aims to
unlock groundbreaking discoveries, drive the development of today’s
and tomorrow’s therapies, and transform patient outcomes.
In addition to expanding its workforce, ATON will actively
pursue strategic international expansion. This strategy will
enhance ATON's research capabilities, expand its technology
portfolio, and foster collaborations with industry-leading experts.
By embracing this growth strategy, ATON aims to create a dynamic
ecosystem that fuels innovation and accelerates the development of
life-saving treatments.
"ATON represents a new era for our company, one that is defined
by our unwavering commitment to advancing breakthrough treatments
and putting the patient at the centre of everything we do," said
Leone Atayi, Chief Executive Officer, ATON. " Our focus is to
invest in the future of medicine and lead the bioscience industry
in the advancement of therapies, for the good of patients,
medicine, and society as a whole. We believe that every patient
deserves treatments that are safer and more effective, tailored to
their unique biology, and our company is determined to make that a
reality. Our re-branding as ATON signifies our renewed focus and
commitment to transform the field of bioscience."
Through collaborations with leading scientists and institutions,
ATON and its portfolio of specialist bioscience companies seek to
uncover new insights into disease mechanisms and discover novel
therapeutic targets by guiding and supporting life science
enterprises.
As ATON embarks on this transformative journey, it remains
rooted in its mission to advance therapies for the good of
patients, medicine, and society. The re-branding of ATON marks a
pivotal moment for the company as it sets its sights on reshaping
the landscape of bioscience and ushering in a new era of
personalized medicine.
For more information about ATON and its leading-edge
technologies for the life sciences industry, please visit
www.aton-group.com.
Notes to Editor
Aton is a lifesciences group invested in the future of medicine,
to improve patient care and treatment safety. Aton guides and grows
a portfolio of leading-edge companies, each deploying a specialism,
working in synergy to advance tomorrow’s therapies.
ATON is the trade name under which Hybrigenics SA operates.
Hybrigenics SA (ALHYG) is listed in Paris on Euronext’s Growth
market, eligible for PEAPME.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926755071/en/
Edel Fitzgerald, Reputation Inc, +35387 606 8263,
efitzgerald@reputation-inc.com Paul Griffin, Reputation Inc, +35387
667 4305, pgriffin@reputation-inc.com
Aton (EU:ALHYG)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aton (EU:ALHYG)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024